GLP-1 & Metabolic
GLP-1 and Mitochondria: A 2026 Review Maps the Axis
GLP-1 drugs touch mitochondrial biogenesis, dynamics and mitophagy. A 2026 Aging Cell review asks how much of that is the receptor, not weight loss.
Semaglutide Cut hsCRP 37.8% in SELECT, Before Weight Loss
Semaglutide lowered hsCRP by 37.8% in SELECT, and the drop appeared by week 4, before major weight loss and also in people who lost no weight.
Retatrutide and Cholesterol: A Post Hoc Look at 2 Trials
Retatrutide was associated with large drops in atherogenic lipoproteins in two phase 2 trials. The analysis was post hoc, and biomarkers are not events.
Semaglutide in MASH: What a 52-Week Biopsy Trial Found
Semaglutide plus an SGLT2 inhibitor beat monotherapy on every histological number in a 52-week MASH trial, and still missed its primary endpoints.
Tirzepatide and Blood Pressure: 32 Trials, Two Signals
Tirzepatide cut hypertension-related adverse events but raised hypotension-related ones across 32 trials, while semaglutide looked neutral on both counts.
SURMOUNT Post Hoc Analysis: What a Composite Endpoint Does and Does Not Show
A post hoc analysis of four SURMOUNT trials counts participants who reached three targets at the same time. The counting method is worth as much attention as the percentages it produces.
Anti-Obesity Medications and Ageing: What a 2026 Review Reports
A narrative review published in August 2026 maps what anti-obesity medications appear to do beyond weight loss, from cardiovascular outcomes to skin laxity, and states plainly where the evidence stops short.